TROG Cancer Research
Members Login   CQMS Login


Primary sponsor: Trans Tasman Radiation Oncology Group (TROG)


Randomised phase II trial of Osimertinib with or without stereotactic radiosurgery for EGFR mutated NSCLC with brain metastases


20-40% of patients with NSCLC will develop brain metastases at some point during their course of the disease. Osimertinib has demonstrated intracranial activity in EFGR mutated NSCLC with leptomeningeal disease in the phase 1 BLOOM study. Stereotactic radiosurgery (SRS) is one of the standard local treatment for patients with limited number of brain metastases. Currently, it is unclear whether adding SRS to Osimertinib will result in superior intracranial disease control in patients with EGFR mutated NSCLC with brain metastases diagnosed de novo or developed while on first line EGFR tyrosine kinase inhibitors (TKIs) such as Erlotinib and Gefinitib.

The aim of this study is to compare the effects of Osimertinib alone versus Osimertinib plus SRS on intra-cranial disease control in EGFR mutated NSCLC with brain metastases diagnosed or developed while on first line EGFR tyrosine kinase inhibitors.

Participating Centres

Current participating centres (PDF)

Accrual Target


Current Accrual

Current accrual graph (PDF)

Expected date of accrual completion

November 2021

Trial chairperson

Dr Chee Lee, St George Hospital, NSW, Australia 
Dr Fiona Hegi-Johnson, Peter MacCallum Cancer Centre, VIC, Australia
Dr Yu Yang Soon, National University Hospital Singapore
Dr Ivan Tham, National University Hospital Singapore
Dr Ross Soo, National University Hospital Singapore

Trial contact

Patrick Wheeler
Clinical Trial Coordinator
TROG Trial Coordinating Centre
Phone: +61 2 4014 3903

Trial resources for TROG members

TROG 17.02 member page

We are thankful to our 14,500 patients who have participated in our research. Please continue the generous support.